Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 8, 2026

Halozyme and Vertex sign deal for Hypercon technology

Halozyme Therapeutics’ subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former’s Hypercon technology.

Halozyme’s Enhanze drug delivery technology supports the subcutaneous administration of injected drugs and fluids. Credit: Gorodenkoff / Shutterstock.com.